CD166 / ALCAM Protein, Human, Recombinant (His Tag)

1/2
Price:
Size:
Number:

CD166 / ALCAM Protein, Human, Recombinant (His Tag): Product Information

Purity
> 98 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Immobilized human ALCAM-His at 10 μg/ml (100 μl/well) can bind mouse CD6-Fc (Cat:50711-M02H), The EC50 of mouse CD6-Fc (Cat:50711-M02H) is 0.1-0.22 μg/ml.
Protein Construction
A DNA sequence encoding the extracellular domain (Met 1-Ala 526) of human ALCAM (NP_001618.2) was expressed, with the C-terminal polyhistidine tag.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Trp 28
Molecule Mass
The recombinant human ALCAM consists of 510 amino acids and has a calculated molecular mass of 57.4 kDa. As a result of glycosylation, rh ALCAM migrates as an approximately 60-70 kDa band in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD166 / ALCAM Protein, Human, Recombinant (His Tag): Images

Immobilized human ALCAM-His at 10 μg/ml (100 μl/well) can bind mouse CD6-Fc (Cat:50711-M02H), The EC50 of mouse CD6-Fc (Cat:50711-M02H) is 0.1-0.22 μg/ml

CD166 / ALCAM Protein, Human, Recombinant (His Tag): Alternative Names

CD166 Protein, Human; MEMD Protein, Human

CD166 / ALCAM Background Information

Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
Full Name
activated leukocyte cell adhesion molecule
References
  • Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
  • Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
  • Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
  • Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.
  • Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells
    Author
    Fernández, MM;Ferragut, F;Cárdenas Delgado, VM;Bracalente, C;Bravo, AI;Cagnoni, AJ;Nuñez, M;Morosi, LG;Quinta, HR;Espelt, MV;Troncoso, MF;Wolfenstein-Todel, C;Mariño, KV;Malchiodi, EL;Rabinovich, GA;Elola, MT;
    Year
    2016
    Journal
    Biochim. Biophys. Acta
    Application
    SPR
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait